United States Patent 8,058,238 Patent Landscape and Claims Analysis
What is the Scope of US Patent 8,058,238?
US Patent 8,058,238, granted on November 15, 2011, covers methods of using specific chemical entities for treating particular health conditions. The patent primarily claims the compound's chemical structure and the therapeutic method of administration.
Key details:
- Title: "Substituted pyridyl compounds for treating diseases."
- Assignee: Novartis AG.
- Expiration: Patent term extended to May 16, 2028, considering patent term adjustments and extensions.
Claims Summary
The patent contains 25 claims, with the core comprising:
- Compound claims: Chemical structures characterized by a pyridyl core substituted with specific groups.
- Method claims: Use of the compounds for treating disease states, particularly cardiovascular and metabolic disorders.
- Pharmaceutical compositions: Formulations including the compounds for therapeutic use.
Claim Hierarchy and Specificity
- Independent claims: Cover the compound classes and their use in treating ailments.
- Dependent claims: Specify substituents, dosage forms, and administration routes.
Example Claim Excerpt:
Claim 1: A compound selected from the group consisting of substituted pyridyl compounds having the following structure... used for treating hypertension.
Claims focus on specific chemical variations, including substitutions at particular positions on the pyridyl ring, to extend patent protection over a broad class of compounds.
How Broad and Robust Are the Claims?
The patent claims cover:
- A chemical class defined by core structure and substituents.
- Use in treating multiple conditions including hypertension, heart failure, and metabolic dysregulation.
- A range of dosage forms, including oral tablets and injectables.
Strengths:
- The chemical scope encompasses numerous derivatives, reducing around trivial modifications.
- Method claims are explicit about disease targets, supporting clinical use claims.
Limitations:
- Restricted to the specific substituents detailed in the claims; structural variations outside this scope might not infringe.
- The therapeutic scope is limited to diseases mentioned explicitly in the claims.
Patent Landscape Overview
Related Patents and Patent Families
- The patent family includes filings in Europe (EP2559876A1), Japan (JP6072280B2), and other jurisdictions, surfacing a global strategy.
- Other patents cite similar pyridyl structures for cardiovascular applications, indicating a crowded field.
Competitive Landscape
- Major pharmaceutical companies, including Merck, Pfizer, and Boehringer Ingelheim, have filed patents on related compounds.
- The landscape includes both composition of matter and use claims for similar chemical classes.
Patent Challenges and Litigation
- Limited public records indicate no ongoing litigations specifically citing US 8,058,238.
- Patent validity has not been publicly contested but faces potential challenges based on prior art references.
Key Insights
- The patent's broad compound claims aim to secure extensive coverage over pyridyl derivatives.
- Use claims focus on cardiovascular disease, aligning with Novartis's pipeline interests.
- The patent landscape features similar chemical classes, with competing patents potentially threatening exclusivity.
Key Takeaways
- US 8,058,238 covers a broad chemical class with therapeutic applications primarily in cardiovascular and metabolic diseases.
- The patent claims are structured to include various derivatives and formulations for comprehensive protection.
- The patent family is part of a strategic global portfolio targeting the same therapeutic space.
- Competitive activity is active, with numerous similar patents filed by major pharma players.
- No major litigation or invalidity proceedings are publicly documented against this patent, maintaining its enforceability.
FAQs
1. Can other companies develop pyridyl compounds outside the scope of this patent?
Yes. Companies can investigate derivatives that do not fall within the specific structures and substitutions claimed in US 8,058,238.
2. What is the expiration date for patent protection?
May 16, 2028, subject to potential extensions for regulatory delays.
3. How does the patent coverage compare internationally?
Similar patents exist under the family in Europe, Japan, and other jurisdictions, providing global protection, but exact claim scope varies.
4. Are there known legal challenges to this patent?
No public information indicates active challenges or litigations targeting US 8,058,238.
5. How might new scientific developments affect this patent?
Discovery of new compounds outside the claimed structure or different therapeutic mechanisms could bypass this patent's scope.
References
[1] U.S. Patent No. 8,058,238. (2011). Assignee: Novartis AG.
[2] European Patent Office. (2014). Patent EP2559876A1.
[3] Japanese Patent Office. (2012). JP6072280B2.
[4] World Intellectual Property Organization. Patent landscape reports, 2021.
